{"pub_date": "2016-07-15T23:45:13+0000", "subsection_name": null, "lead_paragraph": "Six years after the Affordable Care Act cleared the way for biosimilars, as the generic versions of biotechnology drugs are called, progress has been slow.", "print_page": "1", "document_type": "article", "byline": {"person": [{"rank": 1, "organization": "", "lastname": "POLLACK", "firstname": "Andrew", "role": "reported"}], "original": "By ANDREW POLLACK"}, "multimedia": [{"width": 190, "height": 126, "url": "images/2016/07/16/business/16DRUG-1/16DRUG-1-thumbWide.jpg", "subtype": "wide", "legacy": {"wide": "images/2016/07/16/business/16DRUG-1/16DRUG-1-thumbWide.jpg", "widewidth": "190", "wideheight": "126"}, "type": "image"}, {"width": 600, "height": 851, "url": "images/2016/07/16/business/16DRUG-1/16DRUG-1-articleLarge.jpg", "subtype": "xlarge", "legacy": {"xlargewidth": "600", "xlargeheight": "851", "xlarge": "images/2016/07/16/business/16DRUG-1/16DRUG-1-articleLarge.jpg"}, "type": "image"}, {"width": 75, "height": 75, "url": "images/2016/07/16/business/16DRUG-1/16DRUG-1-thumbStandard.jpg", "subtype": "thumbnail", "legacy": {"thumbnail": "images/2016/07/16/business/16DRUG-1/16DRUG-1-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "type": "image"}], "section_name": "Business Day", "headline": {"print_headline": "New Patents Aim to Delay Generics of Biologics", "main": "Makers of Humira and Enbrel Using New Drug Patents to Delay Generic Versions"}, "source": "The New York Times", "blog": [], "word_count": "1057", "web_url": "http://www.nytimes.com/2016/07/16/business/makers-of-humira-and-enbrel-using-new-drug-patents-to-delay-generic-versions.html", "slideshow_credits": null, "news_desk": "Business", "type_of_material": "News", "snippet": "Six years after the Affordable Care Act cleared the way for biosimilars, as the generic versions of biotechnology drugs are called, progress has been slow....", "_id": "5789758c38f0d829e63ddee8", "abstract": "Drug makers Amgen and AbbVie are deploying new patents to delay generic versions of their costly biologics medicines Humira and Enbrel; progress for biosimilars, as generic versions of biotech drugs are called, has been slow in wake of Affordable Care Act.", "keywords": [{"rank": "1", "name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y"}, {"rank": "2", "name": "subject", "value": "Biotechnology and Bioengineering", "is_major": "N"}, {"rank": "3", "name": "subject", "value": "Generic Brands and Products", "is_major": "Y"}, {"rank": "4", "name": "subject", "value": "Prices (Fares, Fees and Rates)", "is_major": "N"}, {"rank": "5", "name": "organizations", "value": "Amgen Inc", "is_major": "Y"}, {"rank": "6", "name": "organizations", "value": "AbbVie Inc", "is_major": "Y"}, {"rank": "7", "name": "subject", "value": "Patient Protection and Affordable Care Act (2010)", "is_major": "Y"}, {"rank": "8", "name": "subject", "value": "Health Insurance and Managed Care", "is_major": "N"}]}